Patents by Inventor Zhijun Kang

Zhijun Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLS1 inhibitors for treating disease
    Patent number: 11958849
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: April 16, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Nut assembly for electronic expansion valve, electronic expansion valve, and limiting element mounting method
    Patent number: 11946555
    Abstract: Disclosed is a nut assembly for an electronic expansion valve, an electronic expansion valve, and a limiting element mounting method. The nut assembly comprises a nut base, having a first end and a second end opposite to each other; a stop guide rail, sleeved on the nut base; a check ring, sleeved on the nut base and capable of helically rotating with respect to the nut base along the stop guide rail; and a limiting element, provided at the first end of the nut base The limiting element mounting method comprises the following steps: enabling the limiting element to be sleeved on the nut base, and enabling a second limiting boss to extend from a groove opening of a first limiting groove into the first limiting groove; and enabling, by means of the limiting element, the second limiting boss to slide into a corresponding second limiting groove.
    Type: Grant
    Filed: May 10, 2020
    Date of Patent: April 2, 2024
    Assignee: ZHEJIANG DUNAN ARTIFICIAL ENVIRONMENT CO., LTD.
    Inventors: Xinnan Wang, Zhijun Kang, Jian Yang
  • Substituted heterocyclic inhibitors of PTPN11
    Patent number: 11932643
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: March 19, 2024
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Jason Cross, Jason Burke, Timothy McAfoos, Zhijun Kang
  • ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES
    Publication number: 20230416261
    Abstract: Provided are ethanediamine-heterocycle compounds, and salts thereof, that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Application
    Filed: September 6, 2023
    Publication date: December 28, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy MCAFOOS, Christopher L. CARROLL, Zhijun KANG
  • ONE-WAY VALVE
    Publication number: 20230265935
    Abstract: A one-way valve is provided. The one-way valve includes a housing and a valve core assembly. The housing is provided with a valve port. A ratio of a wall thickness of the housing to an outer diameter of the housing is in a range of 0.08 and 0.12. The valve core assembly is movably disposed in the housing and configured to open or seal the valve port.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 24, 2023
    Applicant: ZHEJIANG DUNAN ARTIFICIAL ENVIRONMENT CO., LTD.
    Inventors: Yunjun XIONG, Zhou YU, Zhijun KANG
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20230124815
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: April 20, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • NUT ASSEMBLY FOR ELECTRONIC EXPANSION VALVE, ELECTRONIC EXPANSION VALVE, AND LIMITING ELEMENT MOUNTING METHOD
    Publication number: 20220221078
    Abstract: Disclosed is a nut assembly for an electronic expansion valve, an electronic expansion valve, and a limiting element mounting method. The nut assembly comprises a nut base, having a first end and a second end opposite to each other; a stop guide rail, sleeved on the nut base; a check ring, sleeved on the nut base and capable of helically rotating with respect to the nut base along the stop guide rail; and a limiting element, provided at the first end of the nut base The limiting element mounting method comprises the following steps: enabling the limiting element to be sleeved on the nut base, and enabling a second limiting boss to extend from a groove opening of a first limiting groove into the first limiting groove; and enabling, by means of the limiting element, the second limiting boss to slide into a corresponding second limiting groove.
    Type: Application
    Filed: May 10, 2020
    Publication date: July 14, 2022
    Inventors: Xinnan WANG, Zhijun KANG, Jian YANG
  • GLS1 inhibitors for treating disease
    Patent number: 11370786
    Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 28, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11
    Publication number: 20210317122
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: February 3, 2021
    Publication date: October 14, 2021
    Inventors: Philip JONES, Jason CROSS, Jason BURKE, Timothy MCAFOOS, Zhijun KANG
  • Substituted heterocyclic inhibitors of PTPN11
    Patent number: 10954243
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: March 23, 2021
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Jason Cross, Jason Burke, Timothy Mcafoos, Zhijun Kang
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 10894052
    Abstract: The present disclosure relates to heterocyclic compounds and methods which inhibit ATR kinase to treat or prevent cancer.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: January 19, 2021
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Suyambu Kesava Vijayan Ramaswamy, Zhijun Kang, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20200407353
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: December 31, 2020
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Heterocyclic inhibitors of ATR kinase
    Patent number: 10800774
    Abstract: The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: October 13, 2020
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Zhijun Kang, Michael Garrett Johnson, Sarah Lively
  • GLS1 inhibitors for treating disease
    Patent number: 10766892
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11
    Publication number: 20190389867
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: May 1, 2019
    Publication date: December 26, 2019
    Inventors: Philip JONES, Jason CROSS, Jason BURKE, Timothy MCAFOOS, Zhijun KANG
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20190282584
    Abstract: The present disclosure relates to heterocyclic compounds and methods which inhibit ATR kinase to treat or prevent cancer.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 19, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Suyambu Kesava Vijayan RAMASWAMY, Zhijun KANG, Michael Garrett JOHNSON, Sarah LIVELY, David LAPOINTE
  • GLS1 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190270736
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • GLS1 inhibitors for treating disease
    Patent number: 10344025
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: July 9, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • HETEROCYCLIC INHIBITORS OF ATR KINASE
    Publication number: 20190055240
    Abstract: The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Christopher Lawrence CARROLL, Jason Bryant CROSS, Zhijun KANG, Michael Garrett JOHNSON, Sarah LIVELY
  • GLS1 inhibitors for treating disease
    Patent number: 9809588
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 7, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau